FUJIFILM Irvine Scientific Adds Key Products to Its Life Sciences Portfolio from FUJIFILM Wako Chemicals U.S.A.

• Additional products in lab automation, lab chemicals and LAL expand complete solutions available directly from FUJIFILM Irvine Scientific to customers in US and Europe
• Sales agreement aligns business and commercial operations to maximize customer benefit

SANTA ANA, California, September 26, 2024 - FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for the Life Science and Medical markets, today announced further expansion of its product portfolio and enhanced services through the alignment of specific commercial operations with its sister company, FUJIFILM Wako Chemicals U.S.A., Corp. (FUJIFILM Wako Chemicals). Effective October 1, 2024, products from three divisions within the FUJIFILM Wako Chemicals organization - Lab Automation, Lab Chemicals, LAL Group - will be promoted directly from FUJIFILM Irvine Scientific to customers in the United States and Europe.

Both companies carry a rich history of offering quality products and services to their respective customer bases. The creation of a single, global commercial organization through FUJIFILM Irvine Scientific, will provide an expanded suite of products including cell culture solutions, laboratory chemicals, clinical diagnostic reagents, and laboratory automation software and services that will benefit all who work in life sciences.

Each company will maintain distinct business operations for product development, manufacturing facilities, and quality standards, but sales will be driven by FUJIFILM Irvine Scientific's robust Life Sciences business unit.

Since 1970, FUJIFILM Irvine Scientific has been serving customers developing and manufacturing biopharmaceuticals, cell and gene therapy, and regenerative medicine for life science research and drug discovery. With a global network of sales and support operations across the United States, Europe, and Asia, FUJIFILM Irvine Scientific is well positioned to ensure efficient distribution of FUJIFILM Wako products. FUJIFILM Wako Pure Chemical Corporation has a long history in the markets they serve and will continue to sell directly to their customers in Asia.

Through the past several years, the Life Sciences Business Division of FUJIFILM Corporation has been creating synergies within the Fujifilm Group to become more customer-centric in its ability to offer complete solutions tailored for a wide range of customers within life sciences.

"In 2020, FUJIFILM Irvine Scientific began selling iCell products from FUJIFILM Cellular Dynamics, and now we are excited to bring together the right mix of products from all of these Fujifilm teams, leveraging our collective expertise to offer our partners a breadth of life science solutions in one single destination," said Yutaka Yamaguchi, general manager of Life Sciences Business Division, FUJIFILM Corporation. "We are listening to what our partners are asking for and FUJIFILM life sciences companies will continue working together to expand services needed for their future success in the field."

For more information about FUJIFILM Irvine Scientific's product portfolio, please visit https://irvinesci.com

ENDS

Notes to Editors

FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific, Inc. is a global leader in the innovation and manufacture of cell culture solutions for Life Science and Medical markets, providing products and services that assist customers in advancing healthcare initiatives. Working across discovery research, cell and gene therapy, reproductive medicine and cytogenetics, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers, manufacturers, and clinicians worldwide.

For over 50 years, FUJIFILM Irvine Scientific's mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies. The Company's facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.

For more information, please visit: www.irvinesci.com.

FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here.